Clinical Trials Logo

Meniscus Tear clinical trials

View clinical trials related to Meniscus Tear.

Filter by:

NCT ID: NCT05261360 Recruiting - Knee Injuries Clinical Trials

Clinical Efficacy of Exosome in Degenerative Meniscal Injury

KNEEXO
Start date: March 2022
Phase: Phase 2
Study type: Interventional

Comparison of intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes with synovial fluid-derived mesenchymal stem cells on the same patient.

NCT ID: NCT05114694 Recruiting - Meniscus Tear Clinical Trials

Early Arthroscopic Partial Meniscectomy(APM)

Start date: January 15, 2018
Phase: N/A
Study type: Interventional

Arthroscopic partial meniscectomy(APM) surgery outcomes for Metabolic Syndrome(MetS) patients with degenerative meniscus tears(DMTs) was still not clear. The aim of the study was to investigate outcomes of early APM vs delayed APM for MetS patients with degenerate meniscus tears.

NCT ID: NCT04753424 Recruiting - Clinical trials for Patient Satisfaction

Semitendinosus Graft as Meniscal Transplant

Start date: January 1, 2018
Phase:
Study type: Observational

Removal of meniscal tissue is described to result in poor knee function and a significant risk for future development of osteoarthritis. Different implants have been suggested to substitute a removed meniscus. Meniscal allograft transplantation is not widely available due to costs and availability. The semitendinosus tendon is a known graft with biological properties with potential to remodel and revascularize in an intraarticular environment such as anterior cruciate ligament reconstruction. The objective for this study was to investigate whether the semitendinosus tendon graft could function as a meniscal transplant.

NCT ID: NCT04572256 Recruiting - ACL Injury Clinical Trials

MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

MOCHA
Start date: February 1, 2021
Phase: Early Phase 1
Study type: Interventional

This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.